Cannabis operator Curaleaf Holdings Inc (CSE:CURA) (OTCQX:CURLF) reported on Friday the receipt of the Commonwealth's Department of Health, Office of Medical Marijuana clinical registrant status in Pennsylvania, USA.
Under the Commonwealth's medical marijuana research programme, the new clinical registrant designation allows the company to open a cultivation and processing facility as well as up to six dispensaries in Pennsylvania.
Through the clinical registrant status, the company will support research initiatives into the potential medical benefits of cannabis by providing medical cannabis, expertise and distribution to patients participating in studies.
According to Dr Rachel Levine of the Pennsylvania Department of Health, Pennsylvania remains on the forefront for clinical research on medical marijuana. The research will provide physicians with more evidence-based research to make clinical decisions for their patients suffering with cancer, PTSD and other serious medical conditions.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886